Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
CN Bio logo — Generate human-specific efficacy and safety data with Physi...

CN Bio

Generate human-specific efficacy and safety data with PhysioMimix® microphysiological systems.

Founded 2008 United Kingdom Cambridge, United Kingdom 59 employees Series B Total: $43.67M Biopharma, Biotechnology +2

General Information

Company Name CN Bio
Founded Year 2008
Location United Kingdom Cambridge, United Kingdom +1
Employees 59
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Series B
Social

Get notified when CN Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About CN Bio

CN Bio, founded in 2008 and headquartered in the United Kingdom, is a pioneering player in the Biopharma and Biotechnology sectors, specializing in cutting-edge organ-on-a-chip technology.

Their flagship offering, the PhysioMimix® microphysiological systems, is designed to enhance the precision and speed of preclinical drug discovery by replicating human physiological responses. This approach provides a more translatable alternative to conventional animal models, addressing the need for human-specific data critical for advancing new therapeutics.

In April 2024, CN Bio received a substantial $21.00M Series B investment, led by prominent investors CN Innovations and Bayland Capital. With strong market demand and backing, the company is strategically positioned to redefine the drug development landscape, providing valuable tools for more reliable and efficient drug testing.

Taxonomy: Organ-on-a-Chip, Microphysiological Systems, Preclinical Drug Discovery, Safety Toxicology, 3D Cell Culture, Primary Human Cells, Human-Specific Efficacy Data, Disease Modeling, Drug-Induced Liver Injury, Pharmaceutical and Biotech Research, Non-Alcoholic Steatohepatitis, Hepatitis B Disease Model, Precision Biology, Microfluidic Cell Culture, Viral Lifecycle Models

Services & Products

Organ-on-a-chip models
Non-Alcoholic Steatohepatitis studies
Drug-Induced Liver Injury studies
Custom study design for research goals
Multi-chip plates and consumables
Contract research services

Target Customers

Pharmaceutical companies Biotechnology researchers Laboratories focusing on drug efficacy Safety and ADME departments in healthcare

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 2 •••• •••• 23 Apr 2024
Series B •••••• 1
Investor
01 Jul 2021
Grant •••••• 1
Investor
01 Mar 2021
Venture Round •••••• 2
Investor
•••• •••• 		02 Mar 2020
Grant •••••• 1
Investor
11 Oct 2017

View All 6 Funding Rounds

CN Bio Alternatives & Competitors

View All Alternatives
CN Bio vs
Emulate, Inc.
Emulate, Inc. United States

Our Organ-on-a-Chip technology provides a high-fidelity window into the inner workings of human biol...

Series F
71 employees
Biotechnology, Health Care
Compare CN Bio vs Emulate, Inc.
CN Bio vs
Yecuris Corporation
Yecuris Corporation United States

FRG® Liver Humanized Mice & Research Services

Series Unknown
28 employees
Biotechnology, Life Sciences
Compare CN Bio vs Yecuris Corporation
CN Bio vs
Altis Biosystems
Altis Biosystems United States

Capturing the Complexity of the Human Gut

Series A
28 employees
Biotechnology, Health Care
Compare CN Bio vs Altis Biosystems
View all alternatives

FAQ About CN Bio

Generate human-specific efficacy and safety data with PhysioMimix® microphysiological systems.
CN Bio was founded in 2008.
CN Bio is headquartered in Cambridge, United Kingdom.
CN Bio operates in the following industries: Biopharma, Biotechnology, Health Care, Medical Devices.
CN Bio has approximately 59 employees.
CN Bio has completed 6 funding rounds, raising a total of $43.67M. The latest funding stage is Series B.
CN Bio offers: Organ-on-a-chip models, Non-Alcoholic Steatohepatitis studies, Drug-Induced Liver Injury studies, Custom study design for research goals, Multi-chip plates and consumables, Contract research services.
Top alternatives and competitors to CN Bio include Emulate, Inc., Yecuris Corporation, Altis Biosystems, Celogics, Axol Bioscience Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CN Bio and Emulate, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors CN Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy